Evidence map›Paper›PMID 36555494›Full record

ArticleInternational journal of molecular sciences2022

Identification of New Purpuroine Analogues from the Arctic Echinodermata

Sara Ullsten, Guillaume A Petit, Johan Isaksson, Ida K Ø Hansen, Yannik K-H Schneider, Marte Jenssen, Chun Li, Kine Ø Hansen

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sara UllstenMarbio, UiT-The Arctic University of Norway, N-9037 Tromsø, Norway.ORCID 0000-0003-3219-6645
Guillaume A PetitMarbio, UiT-The Arctic University of Norway, N-9037 Tromsø, Norway.ORCID 0000-0002-8251-0754
Johan IsakssonDepartment of Chemistry, UiT-The Arctic University of Norway, N-9037 Tromsø, Norway.ORCID 0000-0001-6287-7594
Ida K Ø HansenNorwegian College of Fishery Science, Faculty of Biosciences, Fisheries and Economics, UiT-The Arctic University of Norway, N-9037 Tromsø, Norway.ORCID 0000-0003-3775-8010
Yannik K-H SchneiderMarbio, UiT-The Arctic University of Norway, N-9037 Tromsø, Norway.ORCID 0000-0001-6506-1187
Marte JenssenMarbio, UiT-The Arctic University of Norway, N-9037 Tromsø, Norway.ORCID 0000-0001-7563-0005
Chun LiMarbio, UiT-The Arctic University of Norway, N-9037 Tromsø, Norway.
Kine Ø HansenMarbio, UiT-The Arctic University of Norway, N-9037 Tromsø, Norway.ORCID 0000-0002-9023-1958

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Isolation of bioactive products from the marine environment is considered a very promising approach to identify new compounds that can be used for further drug development. In this work we have isolated three new compounds from the purpuroine family by mass-guided preparative HPLC; purpuroine K-M. These compounds where screened for antibacterial- and antifungal activity, antibiofilm formation and anti-cell proliferation activity. Additionally, apoptosis-, cell cycle-, kinase binding- and docking studies were performed to evaluate the mechanism-of-action. None of the compounds showed activity in antibacterial-, antibiofilm- or antifungal assays. However, one of the isolated compounds, purpuroine K, showed activity against two cell lines, MV-4-11 and MOLM-13, two AML cell lines both carrying the FTL3-ITD mutation. In MV-4-11 cells, purpuroine K was found to increase apoptosis and arrest cells cycle in G1/G0, which is a common feature of FLT3 inhibitors. Interactions between purpuroine K and the FLT3 wild type or FLT3 ITD mutant proteins could however not be elucidated in our kinase binding and docking studies. In conclusion, we have isolated three novel molecules, purpuroine K-M, one of which (purpuroine K) shows a potent activity against FLT3-ITD mutated AML cell lines, however, the molecular target(s) of purpuroine K still need to be further investigated.

Indexed as

Leukemia, Myeloid, AcuteAnimalsAntifungal AgentsApoptosisCell LineCell Line, TumorEchinodermatafms-Like Tyrosine Kinase 3MutationProtein Kinase InhibitorsAntifungal Agentsfms-Like Tyrosine Kinase 3Protein Kinase InhibitorsFLT3marine bioprospectingmarine Echinodermatamarine secondary metabolitePteraster militarisstructure elucidation

Identifiers

PMID36555494
PMCPMC9779817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.